News | February 07, 2025
Merck reports 2024 sales at $64.2 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research
The biosimilar Ustekinumab has been developed and manufactured by the company
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Harnessing advanced data analysis for early detection, prevention and better outcomes
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Subscribe To Our Newsletter & Stay Updated
